We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnosti... Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. Show more
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3...
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimerโs disease, today announced plans to present a...
$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed...
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimerโs Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimerโs Patients Who Received Simufilam...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1 | 4.75963826749 | 21.01 | 22.46 | 19.47 | 792860 | 20.52759672 | CS |
4 | 1.75 | 8.63770977295 | 20.26 | 26.6757 | 19.435 | 1027882 | 22.1456973 | CS |
12 | -1.49 | -6.34042553191 | 23.5 | 26.6757 | 18.18 | 749221 | 21.92253878 | CS |
26 | 3.63 | 19.7497279652 | 18.38 | 32.1 | 17.45 | 988310 | 23.40460703 | CS |
52 | 0.05 | 0.227686703097 | 21.96 | 32.1 | 12.3202 | 982289 | 21.72005416 | CS |
156 | -18.53 | -45.7079427726 | 40.54 | 146.16 | 12.3202 | 2375116 | 49.61845035 | CS |
260 | 20.89 | 1865.17857143 | 1.12 | 146.16 | 1 | 2783522 | 34.20239022 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions